Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.
Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Song G, et al. Among authors: santos cm. Clin Cancer Res. 2014 Dec 1;20(23):6083-95. doi: 10.1158/1078-0432.CCR-14-0493. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231403 Free PMC article.
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Karginova O, et al. Among authors: santos c. Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474. Mol Cancer Ther. 2015. PMID: 25824335 Free PMC article.
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC. Song G, et al. Among authors: santos cm. Nanomedicine. 2015 Oct;11(7):1797-807. doi: 10.1016/j.nano.2015.05.007. Epub 2015 Jun 17. Nanomedicine. 2015. PMID: 26093057
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Zawistowski JS, et al. Among authors: santos c. Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20. Cancer Discov. 2017. PMID: 28108460 Free PMC article. Clinical Trial.
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK. Van Swearingen AED, et al. Among authors: santos c. Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052. Neuro Oncol. 2017. PMID: 28486691 Free PMC article.
6,066 results